IN THE CLAIMS:

Please amend the claims to read as follows:

1.-82. (Cancelled)

83. (Currently Amended) A method of assessing the effectiveness of a NNRTI on an HIV-infected patient, comprising evaluating whether a plasma sample collected from the HIV-infected patient contains a nucleic acid that has a mutation at codon 190 and codon 101 or 98, wherein the presence of the ~~mutation~~ mutations at codon 190 and codon 101 or 98 is correlated with increased susceptibility to delavirdine and decreased susceptibility to nevirapine and efavirenz.

84. (Previously Presented) The method of claim 83, wherein the mutation at codon 190 encodes alanine (A) or serine (S).

85. (Currently Amended) The method of claim 83, further comprising evaluating whether the nucleic acid encoding reverse transcriptase has an additional ~~mutation(s) at codon 101,~~ mutation at codon 103~~, or a combination thereof~~, wherein the presence of the additional ~~mutation(s)~~ mutation in combination with the ~~mutation~~ mutations at codon 190 and codon 101 or 98 is correlated with decreased susceptibility to delavirdine, nevirapine, and efavirenz.

86. (Currently Amended) The method of claim 85, wherein ~~the mutation at codon 101 encodes glutamic acid (E) and~~ the mutation at codon 103 encodes asparagine (N).

87. (Currently Amended) The method of claim 83, wherein the mutation at codon 101 encodes glutamic acid (E). ~~reverse transcriptase has an additional mutation at codon 98~~.

88. (Currently Amended) The method of claim ~~87~~ 83, wherein the mutation at codon 98 encodes glycine (G).

89. (Previously Presented) The method of claim 83, wherein the HIV-infected patient is being treated with an antiretroviral agent.

90.(10-5.)Cancelled